Remission with carboplatin of paclitaxel resistant primary peritoneal papillary serous carcinoma: case report

被引:0
|
作者
Herrada, J
Kudelka, AP
Tornos, C
Shin, DM
Kavanagh, JJ
Edwards, CL
Verschraegen, CF
机构
[1] UNIV TEXAS,MD ANDERSON CANC CTR,DEPT PATHOL,HOUSTON,TX 77030
[2] SIERRA MED CTR,DEPT MED ONCOL,EL PASO,TX
[3] UNIV TEXAS,MD ANDERSON CANC CTR,DEPT THORAC HEAD & NECK MED ONCOL,HOUSTON,TX 77030
[4] UNIV TEXAS,MD ANDERSON CANC CTR,DEPT CLIN INVEST,HOUSTON,TX 77030
关键词
carboplatin; peritoneal papillary serous carcinoma; paclitaxel;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Primary peritoneal papillary serous adenocarcinoma is histologically identical to ovarian papillary serous adenocarcinoma. This diagnosis is made if the ovaries are of normal size with either no tumor or only minimal surface involvement. We describe a patient with a primary peritoneal papillary serous adenocarcinoma which was resistant to initial therapy with paclitaxel, but subsequently achieved a partial response with carboplatin-based chemotherapy. Accordingly, carboplatin therapy should be considered in paclitaxel resistant primary peritoneal papillary serous carcinoma.
引用
收藏
页码:39 / 41
页数:3
相关论文
共 50 条
  • [21] Phase 2 trial of carboplatin, paclitaxel, and irinotecan in ovarian, fallopian tube, and primary peritoneal cancers
    Escobar, PF
    Markman, M
    Rose, P
    Zanotti, K
    Webster, K
    Belinson, J
    GYNECOLOGIC ONCOLOGY, 2004, 92 (01) : 192 - 196
  • [22] Case of pure ovarian squamous cell carcinoma resistant to combination chemotherapy with paclitaxel and carboplatin but responsive to monotherapy with weekly irinotecan
    Nakamura, Yasuhiko
    Kamei, Toshiaki
    Shinagawa, Masahiro
    Sakamoto, Yuka
    Miwa, Ichiro
    JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH, 2015, 41 (05) : 809 - 812
  • [23] Treatment of uterine papillary serous carcinoma with platinum-based chemotherapy and paclitaxel
    Vaidya, AP
    Littell, R
    Krasner, C
    Duska, LR
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2006, 16 : 267 - 272
  • [24] The use of paclitaxel and platinum-based chemotherapy in uterine papillary serous carcinoma
    Zanotti, KM
    Belinson, JL
    Kennedy, AW
    Webster, KD
    Markman, M
    GYNECOLOGIC ONCOLOGY, 1999, 74 (02) : 272 - 277
  • [26] Response to paclitaxel and carboplatin in metastatic salivary gland cancer: A case report
    Ruzich, JC
    Ciesla, MC
    Clark, JI
    HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2002, 24 (04): : 406 - 410
  • [27] Triplet combination of gemcitabine, carboplatin, and paclitaxel in previously treated, relapsed ovarian and peritoneal carcinoma: an experience in Taiwan
    Liu, FS
    Ho, ESC
    Hung, MJ
    Hwang, SF
    Lu, CH
    Ke, YM
    GYNECOLOGIC ONCOLOGY, 2004, 94 (02) : 393 - 397
  • [28] Combination treatment with paclitaxel, carboplatin and cetuximab in maxillary sinus cancer: A case report
    Morimoto, Masahiro
    Takano, Masashi
    Sato, Takehiko
    Makino, Shujiroh
    ONCOLOGY LETTERS, 2024, 27 (03)
  • [29] Mesonephric adenocarcinoma treated with paclitaxel-carboplatin adjuvant chemotherapy: a case report
    Noh, J. J.
    Jung, H.
    Choi, C. H.
    EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 2019, 40 (04) : 679 - 683
  • [30] Paclitaxel, carboplatin and pegylated liposomal doxorubicin in ovarian and peritoneal carcinoma: A phase I study of the Gynecologic Oncology Group
    Rose, Peter G.
    Greer, Benjamin E.
    Horowitz, Ira R.
    Markman, Maurie
    Fusco, Nancy
    GYNECOLOGIC ONCOLOGY, 2007, 104 (01) : 114 - 119